 |
|
|
| |
Safety and Efficacy of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Adults With Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
|
| |
| |
Reported by Jules Levin
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Alexander Wong1; Deborah Goldstein2; Josep Mallolas3; Edwin DeJesus4; Margaret Johnson5; Jean-Michel Molina6; Anton Pozniak7; Anthony Rodgers8; Valerie Teal8; Deborah Hepler8; Sushma Kumar8; Peter Sklar8; George J Hanna8; Carey Hwang8; Cyrus Badshah8; Hedy Teppler8
1Department of Medicine, University of Saskatchewan, Regina, Canada; 2Whitman-Walker Institute, Department of Clinical Research, Washington, DC, USA; 3University of Barcelona, Hospital Clinic-IDIBAPS, Barcelona, Spain; 4Orlando Immunology Center, Department of Clinical Research, Orlando, FL, USA; 5Royal Free London NHS Foundation Trust, Department of HIV Medicine, London, UK; 6University of Paris Diderot, Hôpital Saint-Louis, Paris, France; 7Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK; 8Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
